Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Each has a specific effect on the body
In return for granting Novo the license to use the platform for the lead GLP-1 program, Ascendis is in line for up to $285 million in combined upfront, development and regulatory milestone payments, plus potential tiered royalties
94 , e01083-20 (2020)
[25] [26] Based on its overexpression in a majority of human tumor cell lines and prevalence in chemotherapeutic-resistant tumors, GSTP1-1 is thought to play a role in the development of cancer and its potential resistance to drug treatment
2019;42(Suppl 1):S10323
Orforglipron (Foundayo) is a more convenient option than GLP-1 injections, but is not as clinically effective as GLP-1 injections
US$ 23.26
US$ 24.33
US$ 27.41
US$ 24.45
US$ 29.40
